Opinion|Videos|July 29, 2024
Erythroid Maturating Agents (EMAs) for Frontline or Second-Line Treatment of Anemia in LR-MDS
Author(s)Guillermo Garcia-Manero, MD
An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the role of EMAs for LR-MDS:
- How would you identify patients that are suitable for EMAs for first-line or second-line treatment of anemia?
- How would you identify patients that are suitable for EMAs for first-line or second-line treatment of anemia?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5